EP159/#428 Real-world experience and common adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer. (4th December 2022)

• Record Type: Journal Article
• Authors: Zammarrelli, William; Espino, Kevin; Yeoshoua, Effi; Ehmann, Sarah; Rubinstein, Maria; Green, Angela; Makker, Vicky
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A111
• Page End: A112
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.250
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: To evaluate the toxicity of combination lenvatinib plus pembrolizumab for the treatment of recurrent uterine cancer in a real-world setting. Methods: We retrospectively reviewed patients with a diagnosis of uterine cancer who were treated with lenvatinib plus pembrolizumab at our institution between 9/1/21–1/31/22. Adverse events were manually extracted through chart review and graded according to Common Terminology Criteria for Adverse Events Version 5.0. Results: Forty-three patients were treated with combination lenvatinib plus pembrolizumab with a median age of 67 years (range, 54–85). The most common histologies were serous (35%), endometrioid (23%), and carcinosarcoma (21%). Lenvatinib plus pembrolizumab was second-line treatment in 13 patients (30%), third-line treatment in 15 patients (35%), and fourth-line treatment or beyond in 15 patients (35%). The median number of cycles received was 8 (range, 1–37). Nineteen patients (44%) had a primary dose reduction and 17 patients (40%) required at least one lenvatinib dose reduction during treatment. Three patients (7%) discontinued lenvatinib and 1 patient (2%) discontinued pembrolizumab for intolerance or adverse event. Forty-one patients (98%) experienced an adverse event; 36 (86%) experienced a grade 3 or higher adverse event. The most common grade 3 or higher adverse events were hypertension, anemia, weight loss, fatigue, and thrombocytopenia. Conclusions: In clinical practice, adverse events associated with combination lenvatinib plus pembrolizumab are common and comparable to the experience in KEYNOTE-775. Primary dose reductions were common and most patients continued treatment. Efficacy results are forthcoming.